Trial Profile

Open-Label, Phase 1/2 Study Evaluating the Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, and the Tolerability and Antitumor Activity of Selinexor Combination Treatment (SPRINT)

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 24 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Docetaxel (Primary) ; Pembrolizumab (Primary) ; Selinexor (Primary) ; Fluorouracil; Folinic acid; Irinotecan
Indications Colorectal cancer; Non-small cell lung cancer; Solid tumours
Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
Acronyms SPRINT
Sponsors Karyopharm Therapeutics

19 Mar 2025 Status changed from active, no longer recruiting to completed.
06 May 2024 Planned End Date changed from 1 Mar 2024 to 1 Mar 2025.
06 May 2024 Planned primary completion date changed from 1 Mar 2024 to 1 Mar 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com